[A19-11] Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 15.08.2019
Commission awarded on 04.02.2019 by the Federal Joint Committee (G-BA).
Treatment-naive adults with intermediate/poor-risk advanced renal cell carcinoma
Indication of considerable added benefit for intermediate risk profile; indication of major added benefit for poor risk profile
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.